JP2007513872A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007513872A5 JP2007513872A5 JP2006536096A JP2006536096A JP2007513872A5 JP 2007513872 A5 JP2007513872 A5 JP 2007513872A5 JP 2006536096 A JP2006536096 A JP 2006536096A JP 2006536096 A JP2006536096 A JP 2006536096A JP 2007513872 A5 JP2007513872 A5 JP 2007513872A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl
- compound
- substituted
- branched
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 claims 50
- -1 trifluoromethoxy, nitro, amino Chemical group 0.000 claims 41
- 125000000217 alkyl group Chemical group 0.000 claims 36
- 229910052757 nitrogen Inorganic materials 0.000 claims 28
- 229940002612 prodrug Drugs 0.000 claims 28
- 239000000651 prodrug Substances 0.000 claims 28
- 150000003839 salts Chemical class 0.000 claims 28
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 27
- 102000005962 receptors Human genes 0.000 claims 26
- 108020003175 receptors Proteins 0.000 claims 26
- 125000001424 substituent group Chemical group 0.000 claims 23
- 229910052717 sulfur Inorganic materials 0.000 claims 23
- 230000000694 effects Effects 0.000 claims 22
- 125000000623 heterocyclic group Chemical group 0.000 claims 22
- 229910052760 oxygen Inorganic materials 0.000 claims 21
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 21
- 125000005842 heteroatom Chemical group 0.000 claims 19
- 238000011282 treatment Methods 0.000 claims 18
- 208000008589 Obesity Diseases 0.000 claims 16
- 235000020824 obesity Nutrition 0.000 claims 16
- 125000004076 pyridyl group Chemical group 0.000 claims 16
- 125000003545 alkoxy group Chemical group 0.000 claims 15
- 125000001153 fluoro group Chemical group F* 0.000 claims 15
- 125000001544 thienyl group Chemical group 0.000 claims 15
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 15
- 239000003814 drug Substances 0.000 claims 14
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 14
- 102000004882 Lipase Human genes 0.000 claims 13
- 108090001060 Lipase Proteins 0.000 claims 13
- 239000004367 Lipase Substances 0.000 claims 13
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 13
- 230000002401 inhibitory effect Effects 0.000 claims 13
- 125000000468 ketone group Chemical group 0.000 claims 13
- 235000019421 lipase Nutrition 0.000 claims 13
- 125000003342 alkenyl group Chemical group 0.000 claims 12
- 229920006395 saturated elastomer Polymers 0.000 claims 12
- 125000003118 aryl group Chemical group 0.000 claims 11
- 239000003555 cannabinoid 1 receptor antagonist Substances 0.000 claims 10
- 229940079593 drug Drugs 0.000 claims 10
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 9
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 9
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 9
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 8
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims 8
- 125000004663 dialkyl amino group Chemical group 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 229910052736 halogen Inorganic materials 0.000 claims 8
- 150000002367 halogens Chemical class 0.000 claims 8
- 125000002950 monocyclic group Chemical group 0.000 claims 8
- 125000001624 naphthyl group Chemical group 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 125000006413 ring segment Chemical group 0.000 claims 8
- 125000000081 (C5-C8) cycloalkenyl group Chemical group 0.000 claims 7
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 7
- 230000002265 prevention Effects 0.000 claims 7
- 125000005034 trifluormethylthio group Chemical group FC(S*)(F)F 0.000 claims 7
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 6
- 125000004429 atom Chemical group 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 claims 6
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 5
- 125000003277 amino group Chemical group 0.000 claims 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 5
- 238000011321 prophylaxis Methods 0.000 claims 5
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- 208000006011 Stroke Diseases 0.000 claims 4
- QMHAHUAQAJVBIW-UHFFFAOYSA-N [methyl(sulfamoyl)amino]methane Chemical compound CN(C)S(N)(=O)=O QMHAHUAQAJVBIW-UHFFFAOYSA-N 0.000 claims 4
- 150000001602 bicycloalkyls Chemical group 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- 206010015037 epilepsy Diseases 0.000 claims 4
- 125000003386 piperidinyl group Chemical group 0.000 claims 4
- 125000003373 pyrazinyl group Chemical group 0.000 claims 4
- 125000002098 pyridazinyl group Chemical group 0.000 claims 4
- 125000004306 triazinyl group Chemical group 0.000 claims 4
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 3
- SIKWOTFNWURSAY-UHFFFAOYSA-N Lipstatin Natural products CCCCCCC1C(CC(CC=CCC=CCCCCC)C(=O)OC(CC(C)C)NC=O)OC1=O SIKWOTFNWURSAY-UHFFFAOYSA-N 0.000 claims 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 3
- 230000003042 antagnostic effect Effects 0.000 claims 3
- 125000002619 bicyclic group Chemical group 0.000 claims 3
- MVCQKIKWYUURMU-UHFFFAOYSA-N cetilistat Chemical compound C1=C(C)C=C2C(=O)OC(OCCCCCCCCCCCCCCCC)=NC2=C1 MVCQKIKWYUURMU-UHFFFAOYSA-N 0.000 claims 3
- 229950002397 cetilistat Drugs 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 3
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- OQMAKWGYQLJJIA-CUOOPAIESA-N lipstatin Chemical compound CCCCCC[C@H]1[C@H](C[C@H](C\C=C/C\C=C/CCCCC)OC(=O)[C@H](CC(C)C)NC=O)OC1=O OQMAKWGYQLJJIA-CUOOPAIESA-N 0.000 claims 3
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims 3
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 3
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 claims 3
- 229960001243 orlistat Drugs 0.000 claims 3
- 239000001301 oxygen Substances 0.000 claims 3
- 229920000642 polymer Polymers 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims 3
- 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 claims 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 3
- 239000011593 sulfur Substances 0.000 claims 3
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 claims 3
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 2
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 2
- ZEWJFUNFEABPGL-UHFFFAOYSA-N 1,2,4-triazole-3-carboxamide Chemical class NC(=O)C=1N=CNN=1 ZEWJFUNFEABPGL-UHFFFAOYSA-N 0.000 claims 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical class C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 2
- MCGBIXXDQFWVDW-UHFFFAOYSA-N 4,5-dihydro-1h-pyrazole Chemical class C1CC=NN1 MCGBIXXDQFWVDW-UHFFFAOYSA-N 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 208000027559 Appetite disease Diseases 0.000 claims 2
- 201000006474 Brain Ischemia Diseases 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 2
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 2
- 208000028698 Cognitive impairment Diseases 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- 208000016192 Demyelinating disease Diseases 0.000 claims 2
- 206010012305 Demyelination Diseases 0.000 claims 2
- 206010012335 Dependence Diseases 0.000 claims 2
- 206010012735 Diarrhoea Diseases 0.000 claims 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims 2
- 208000014094 Dystonic disease Diseases 0.000 claims 2
- 206010014612 Encephalitis viral Diseases 0.000 claims 2
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 2
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 2
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 2
- 208000010412 Glaucoma Diseases 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 229930194542 Keto Natural products 0.000 claims 2
- 208000007101 Muscle Cramp Diseases 0.000 claims 2
- 206010028813 Nausea Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000012902 Nervous system disease Diseases 0.000 claims 2
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims 2
- 208000025966 Neurological disease Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 208000028017 Psychotic disease Diseases 0.000 claims 2
- 208000034189 Sclerosis Diseases 0.000 claims 2
- 206010040070 Septic Shock Diseases 0.000 claims 2
- 208000005392 Spasm Diseases 0.000 claims 2
- 208000007107 Stomach Ulcer Diseases 0.000 claims 2
- 208000000323 Tourette Syndrome Diseases 0.000 claims 2
- 208000016620 Tourette disease Diseases 0.000 claims 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 2
- 206010044565 Tremor Diseases 0.000 claims 2
- 206010047700 Vomiting Diseases 0.000 claims 2
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 125000004103 aminoalkyl group Chemical group 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 125000002393 azetidinyl group Chemical group 0.000 claims 2
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 229930003827 cannabinoid Natural products 0.000 claims 2
- 239000003557 cannabinoid Substances 0.000 claims 2
- 230000002490 cerebral effect Effects 0.000 claims 2
- 206010008118 cerebral infarction Diseases 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 claims 2
- 208000010643 digestive system disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 206010013663 drug dependence Diseases 0.000 claims 2
- 208000010118 dystonia Diseases 0.000 claims 2
- 201000005917 gastric ulcer Diseases 0.000 claims 2
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 125000004404 heteroalkyl group Chemical group 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 claims 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 206010027175 memory impairment Diseases 0.000 claims 2
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 230000008693 nausea Effects 0.000 claims 2
- 208000004296 neuralgia Diseases 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 208000021722 neuropathic pain Diseases 0.000 claims 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims 2
- 208000020016 psychiatric disease Diseases 0.000 claims 2
- 208000023504 respiratory system disease Diseases 0.000 claims 2
- 230000036303 septic shock Effects 0.000 claims 2
- 208000020431 spinal cord injury Diseases 0.000 claims 2
- 208000011117 substance-related disease Diseases 0.000 claims 2
- 125000004434 sulfur atom Chemical group 0.000 claims 2
- 230000005062 synaptic transmission Effects 0.000 claims 2
- 150000007979 thiazole derivatives Chemical class 0.000 claims 2
- 230000008733 trauma Effects 0.000 claims 2
- 230000009529 traumatic brain injury Effects 0.000 claims 2
- 125000004950 trifluoroalkyl group Chemical group 0.000 claims 2
- 201000002498 viral encephalitis Diseases 0.000 claims 2
- 230000008673 vomiting Effects 0.000 claims 2
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 1
- 125000006553 (C3-C8) cycloalkenyl group Chemical group 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000019802 Sexually transmitted disease Diseases 0.000 claims 1
- 208000027520 Somatoform disease Diseases 0.000 claims 1
- KPCZJLGGXRGYIE-UHFFFAOYSA-N [C]1=CC=CN=C1 Chemical group [C]1=CC=CN=C1 KPCZJLGGXRGYIE-UHFFFAOYSA-N 0.000 claims 1
- 125000004471 alkyl aminosulfonyl group Chemical group 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 229940065144 cannabinoids Drugs 0.000 claims 1
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 1
- 230000006735 deficit Effects 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- APVPOHHVBBYQAV-UHFFFAOYSA-N n-(4-aminophenyl)sulfonyloctadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 APVPOHHVBBYQAV-UHFFFAOYSA-N 0.000 claims 1
- 230000003959 neuroinflammation Effects 0.000 claims 1
- 208000027753 pain disease Diseases 0.000 claims 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
- 0 C*(C(*=C(*1*=C(*)C(*)(*)C1)S)=*)S Chemical compound C*(C(*=C(*1*=C(*)C(*)(*)C1)S)=*)S 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03103961 | 2003-10-24 | ||
| EP03103967 | 2003-10-27 | ||
| PCT/EP2004/052639 WO2005039550A2 (en) | 2003-10-24 | 2004-10-22 | Novel medical uses of compounds showing cb1-antagonistic activity and combination treatment involving said compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007513872A JP2007513872A (ja) | 2007-05-31 |
| JP2007513872A5 true JP2007513872A5 (enExample) | 2007-09-13 |
Family
ID=34524748
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006536096A Withdrawn JP2007513872A (ja) | 2003-10-24 | 2004-10-22 | Ｃｂ１拮抗作用を示す化合物の新規の医学的用途および前記化合物を伴う組み合わせ治療 |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1753413A2 (enExample) |
| JP (1) | JP2007513872A (enExample) |
| AU (1) | AU2004283056A1 (enExample) |
| BR (1) | BRPI0415851A (enExample) |
| CA (1) | CA2543338A1 (enExample) |
| MX (1) | MXPA06004434A (enExample) |
| RU (1) | RU2006117627A (enExample) |
| WO (1) | WO2005039550A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1575901B1 (en) | 2002-12-19 | 2012-10-10 | Merck Sharp & Dohme Corp. | Substituted amides |
| TW200528102A (en) * | 2003-10-24 | 2005-09-01 | Solvay Pharm Gmbh | Novel medical combination treatment of obesity involving 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity |
| MX2007003325A (es) | 2004-09-20 | 2007-06-05 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como inhibidores estearoil-coa-desaturasa. |
| EP1830837B1 (en) | 2004-09-20 | 2013-09-04 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes |
| JP5149009B2 (ja) | 2004-09-20 | 2013-02-20 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | ヒトステアロイル−ＣｏＡデサチュラーゼを阻害するためのピリダジン誘導体 |
| MX2007003332A (es) | 2004-09-20 | 2007-06-05 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como inhibidores de estearoil-coa-desaturasa. |
| AR051090A1 (es) | 2004-09-20 | 2006-12-20 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa |
| AR051093A1 (es) | 2004-09-20 | 2006-12-20 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como inhibidores de estearoil-coa desaturasa |
| AU2005286728A1 (en) | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase |
| EP2029138A1 (en) | 2005-06-03 | 2009-03-04 | Xenon Pharmaceuticals Inc. | Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors |
| EP1921073A1 (en) | 2006-11-10 | 2008-05-14 | Laboratorios del Dr. Esteve S.A. | 1,2,4-Triazole derivatives as sigma receptor inhibitors |
| WO2024154047A1 (en) * | 2023-01-18 | 2024-07-25 | Brien Holden Vision Institute Limited | Compositions and/or methods for prevention and/or treatment of dry eye disorders |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3003148B2 (ja) * | 1989-01-05 | 2000-01-24 | 藤沢薬品工業株式会社 | チアゾール化合物、その製造法およびそれを含有する医薬組成物 |
| AU3201095A (en) * | 1994-07-27 | 1996-02-22 | G.D. Searle & Co. | Substituted thiazoles for the treatment of inflammation |
| US5616601A (en) * | 1994-07-28 | 1997-04-01 | Gd Searle & Co | 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation |
| US6492516B1 (en) * | 1999-05-14 | 2002-12-10 | Merck & Co., Inc. | Compounds having cytokine inhibitory activity |
| KR100846614B1 (ko) * | 2001-03-22 | 2008-07-16 | 솔베이 파마슈티칼스 비. 브이 | Ｃｂ1-길항 활성을 갖는 4,5-디하이드로-1ｈ-피라졸 유도체 |
| CA2456606C (en) * | 2001-09-21 | 2010-01-26 | Solvay Pharmaceuticals B.V. | 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity |
| TWI231757B (en) * | 2001-09-21 | 2005-05-01 | Solvay Pharm Bv | 1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity |
| US6974810B2 (en) * | 2001-09-21 | 2005-12-13 | Solvay Pharmaceuticals B.V. | 4,5-Dihydro-1H-pyrazole derivatives having potent CB1-antagonistic activity |
| UY27450A1 (es) * | 2001-09-24 | 2003-04-30 | Bayer Corp | Preparación y uso de derivados de imidazol para el tratamiento de la obesidad |
| WO2003039451A2 (en) * | 2001-11-08 | 2003-05-15 | Fujisawa Pharmaceutical Co., Ltd. | Thiazole pyridazinones as adenosine antagonists |
| TW200407110A (en) * | 2001-11-23 | 2004-05-16 | Astrazeneca Ab | New use for the treatment of gastroesophageal reflux disease |
| WO2003063781A2 (en) * | 2002-01-29 | 2003-08-07 | Merck & Co., Inc. | Substituted imidazoles as cannabinoid receptor modulators |
| AR038966A1 (es) * | 2002-03-18 | 2005-02-02 | Solvay Pharm Bv | Derivados de tiazol que tienen actividad antagonista, agonista o agonista parcial de cb1 |
| TW200412942A (en) * | 2002-08-06 | 2004-08-01 | Abbott Lab | Appetite control method |
| HRP20050053A2 (en) * | 2002-09-19 | 2005-04-30 | Solvay Pharmaceuticals B.V. | 1 h-1,2,4-triazole-3-carboxamide derivatives as cannabinoid-cb1 receptor ligands |
| GB0230087D0 (en) * | 2002-12-24 | 2003-01-29 | Astrazeneca Ab | Therapeutic agents |
-
2004
- 2004-10-22 WO PCT/EP2004/052639 patent/WO2005039550A2/en not_active Ceased
- 2004-10-22 MX MXPA06004434A patent/MXPA06004434A/es not_active Application Discontinuation
- 2004-10-22 AU AU2004283056A patent/AU2004283056A1/en not_active Abandoned
- 2004-10-22 JP JP2006536096A patent/JP2007513872A/ja not_active Withdrawn
- 2004-10-22 CA CA002543338A patent/CA2543338A1/en not_active Abandoned
- 2004-10-22 RU RU2006117627/04A patent/RU2006117627A/ru not_active Application Discontinuation
- 2004-10-22 EP EP04817279A patent/EP1753413A2/en not_active Withdrawn
- 2004-10-22 BR BRPI0415851-2A patent/BRPI0415851A/pt not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112601750B (zh) | Ptpn11（shp2）抑制剂 | |
| JP4890723B2 (ja) | ＴＮＦαインヒビターとして有用なクマリン誘導体 | |
| RU2006101452A (ru) | Пиридазинил-пиперазины и их применение в качестве лигандов h3 гистаминового рецептора | |
| RU2006131132A (ru) | 1,3,5,-тризамещенные производные 4,5-дигидро-1н-пиразола, обладающие св1-антагонистической активностью | |
| RU2003130268A (ru) | Производные 4,5-дигидро-1h-пиразола, обладающие сильной cb1-антагонистической активностью | |
| CA2456606A1 (en) | 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity | |
| MX2010006182A (es) | Derivados de isoxazolo-piridazina. | |
| JP2007513872A5 (enExample) | ||
| JP2010510987A5 (enExample) | ||
| JP6380777B2 (ja) | ＰＩ３Ｋ、ｍＴＯＲ阻害薬としての縮合キノリン化合物 | |
| JP2020516591A (ja) | Ｍｏｒアゴニストおよびｋｏｒアゴニストを含有する医薬組成物、およびその用途 | |
| WO2004026306A3 (en) | Pyrazole derivatives as transforming growth factor (tgf) inhibitors | |
| US12391664B2 (en) | GluN2C/D subunit selective antagonists of the N-methyl-D-aspartate receptor | |
| JPWO2021053555A5 (enExample) | ||
| CA3178372A1 (en) | Enpp1 modulators and uses thereof | |
| JP2016525104A5 (enExample) | ||
| RU2006117627A (ru) | Новые применения в медицине соединений, обладающих антагонистической активностью по отношению к св1, и комбинированное лечение с применением этих соединений | |
| JP2004507527A5 (enExample) | ||
| TW200927127A (en) | Agent for overcoming resistance to anti-cancer agent | |
| RU2007116987A (ru) | Новые соединения | |
| JP2006500315A (ja) | 糖尿病状態に用いるヒスタミン−３受容体リガンド | |
| JP2022514685A (ja) | ペンタミジンの類似体及びその使用 | |
| JP2023533616A (ja) | Ｍｎｋ阻害を示すピリジン－１，５－ジオン及びそれらの使用方法 | |
| EP1623741A2 (en) | Cannabinoid receptor ligands for hair growth modulation | |
| CN114853746A (zh) | 甲酰胺类化合物、其制备方法及其在医药上的应用 |